Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2017 April;69(2) > Minerva Urologica e Nefrologica 2017 April;69(2):153-8



Publication history
Cite this article as


A Journal on Nephrology and Urology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,984




Minerva Urologica e Nefrologica 2017 April;69(2):153-8

DOI: 10.23736/S0393-2249.16.02740-5


language: English

Robot assisted retroperitoneal lymph-node dissection after adjuvant therapy: different indications

Victor E., CORONA MONTES 1, 2, Antonio L. PASTORE 1, 3, Louis GAUSA 1, Oscar RODRÍGUEZ-FABA 1, Alberto BREDA 1, Joan PALOU 1

1 Department of Urology, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain; 2 Department of Uro-Oncology, Faculty of Medicine, National University of México (UNAM), General Hospital of México, Mexico City, Mexico; 3 Urology Unit, Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy


BACKGROUND: Today, access to technology through robotic surgery has allowed urologists to have a valuable tool in order to perform various robot -assisted laparoscopic procedures. Robotic surgery allows reproducing complex techniques such as retroperitoneal or extended pelvic lymphadenectomy. The aim of the study was to report our series of robot assisted retroperitoneal lymphadenectomy and to demonstrate its technical and oncological feasibility.
METHODS: A retrospective analysis on 7 patients (four cases of testicular tumors, one prostate adenocarcinoma, and two bladder urothelial carcinomas), who underwent retroperitoneal para-aortic, interaorto-cava and extended pelvic lymphadenectomy by robot assisted laparoscopic surgery, was conducted. We analyzed demographic, oncologic and operative data (surgical time, blood loss, and hospital stay).
RESULTS: Demographic and operative data showed a mean age of 49 years (18-65), mean BMI of 26.1 kg/m2(23.7-29.1), mean operative time of198 minutes (180-220), mean estimated blood loss of 88 mL, and mean hospital stay of 3.6 days (3-5). No intraoperative complications occurred. Themean number of dissected nodes was 12 (3-20). Histopathology findings showed one case of postchemotherapy recurrenceof seminoma and six cases of fibrosis. At a mean postoperative follow-up of 39 months (7-75) no patients showed disease recurrence.
CONCLUSIONS: Our case series demonstrated that the robot assisted approach isa feasible and reproducible option in skilled robotic surgical referral centers. The surgeons’ experience and the optical magnification, associated to the degree of freedom offered by robotic assisted laparoscopy allow achievinga precise lymph node dissection, also in advanced oncologic patients.

KEY WORDS: Lymph node excision - Retroperitoneal space - Chemotherapy, adjuvant - Robotic surgical procedures

top of page

Publication History

Issue published online: February 28, 2017
Article first published online: September 28, 2016
Manuscript accepted: September 26, 2016
Manuscript revised: September 7, 2016
Manuscript received: May 27, 2016

Cite this article as

Corona Montes VE, Pastore AL, Gausa L, Rodríguez-Faba O, Breda A, Palou J. Robot assisted retroperitoneal lymph-node dissection after adjuvant therapy: different indications. Minerva Urol Nefrol 2017;69:153-8. DOI: 10.23736/S0393-2249.16.02740-5

Corresponding author e-mail